Loading...

Nuvation Bio Inc.

NUVB-WT•NYSE
Healthcare
Biotechnology
$0.28
$0.03(11.88%)

Nuvation Bio Inc. (NUVB-WT) Stock Overview

Explore Nuvation Bio Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.4/100

Key Financials

Market Cap773.1M
P/E Ratio-1.29
EPS (TTM)N/A
ROE-1.48%
Fundamental Analysis

AI Price Forecasts

1 Week$0.24
1 Month$0.25
3 Months$0.19
1 Year Target$0.33

NUVB-WT Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Nuvation Bio Inc. (NUVB-WT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 55.65, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.33.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.29 and a market capitalization of 773.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

55.65RSI (14)
0.01MACD
11.11ADX
Stats data is not available for NUVB-WTStats details for NUVB-WT are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NUVB-WTAnalyst Recommendations details for NUVB-WT are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Employees

220

Headquarters

New York City, DE

Founded

1970

Frequently Asked Questions

;